Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib

Cancer

Volumn 120, Issue 15, 2014, Pages 2325-2333

  Joensuu, Heikki ^a   Eriksson, Mikael ^b   Hall, Kirsten Sundby ^c   Hartmann, Jörg T ^d   Pink, Daniel ^e   Schütte, Jochen ^f   Ramadori, Giuliano ^g   Hohenberger, Peter ^h   Duyster, Justus ⁱ   Al Batran, Salah Eddin ^j   Schlemmer, Marcus ^k   Bauer, Sebastian ^l   Wardelmann, Eva ^m   Sarlomo Rikala, Maarit ^a   Nilsson, Bengt ⁿ   Sihto, Harri ^o   Ballman, Karla V ^p   Leinonen, Mika ^q   Dematteo, Ronald P ^r   Reichardt, Peter ^e  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF KIEL   (Germany)

^e HELIOS KLINIKUM BERLIN BUCH   (Germany)

^f Schwerpunktpraxis für Onkologie Hämatologie und Ambulante Tumortherapie ^*  (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j KRANKENHAUS NORDWEST   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l UNIVERSITY HOSPITAL ESSEN   (Germany)

^m UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁿ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^o UNIVERSITY OF HELSINKI   (Finland)

^p MAYO CLINIC   (United States)

^q 4Pharma Ltd   (Finland)

^r MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

adjuvant therapy; gastrointestinal stromal tumor; imatinib; predictive score

Indexed keywords

IMATINIB; PLACEBO; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CELL COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MITOSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMORS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PYRIMIDINES; RISK FACTORS;

EID: 84904759514     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28669     Document Type: Article

References (19)

1. Corless CL, Barnett CM, Heinrich MC,. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011; 11: 865-878.
2. Joensuu H, Hohenberger P, Corless CL,. Gastrointestinal stromal tumour. Lancet. 2013; 382: 973-983.
3. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299: 708-710.
4. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology. 2003; 125: 660-667.
5. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 (suppl 7): vii49-vii55.
6. National Comprehensive Cancer Center. Clinical practice guidelines in oncology: Soft tissue sarcoma. http://www.nccn.org/professionals/physician-gls/ f-guidelines.asp. Accessed November 9, 2013.
7. DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373: 1097-1104.
8. Casali P,. Imatinib failure-free survival in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib: The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. J Clin Oncol. 2013; 31: (suppl): 632s.
9. Joensuu H, Eriksson M, Sundby Hall K, et al. One versus three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA. 2012; 307: 1265-1272.
10. DeMatteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008; 112: 608-615.
11. Joensuu H, Vehtari A, Riihimäki J, et al. Risk of gastrointestinal stromal tumour recurrence after surgery: an analysis based on pooled population-based cohorts. Lancet Oncol. 2012; 13: 265-274.
12. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002; 33: 459-465.
13. Harrell FE Jr, Califf RM, Pryor DB, et al. Evaluating the yield of medical tests. JAMA. 1982; 247: 2543-2546.
14. Bonetti M, Gelber RD,. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics. 2004; 5: 465-481.
15. DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) Intergroup phase 2 trial. Ann Surg. 2013; 258: 422-429.
16. Gal R, Rath-Wolfson L, Rosenblatt Y, et al. An improved technique for mitosis counting. Int J Surg Pathol. 2005; 13: 161-165.
17. Cross SS, Start RD, Smith JH,. Does delay in fixation affect the number of mitotic figures in processed tissue? J Clin Pathol. 1990; 43: 597-599.
18. Huang HY, Huang WW, Lin CN, et al. Immunohistochemical expression of p16INK4A, Ki-67, and Mdm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol. 2006; 13: 1633-1644.
19. Fujita A, Yamamoto H, Imamura M, et al. Expression level of the mitotic checkpoint protein and G2-M cell cycle regulators and prognosis in gastrointestinal stromal tumors in the stomach. Virchows Arch. 2012; 460: 163-169.